The clinical outcome of sarcoidosis is quite variable. Several scoring systems have been used to assess the level of disease and clinical outcome. The definition of clinical phenotypes has become an important goal as genetic studies have identified distinct genotypes associated with different clinical phenotypes. In addition, treatment strategies have been developed for patients with resolving versus non resolving disease. A task force was established by the World Association of Sarcoidosis and Other Granulomatous diseases (WASOG) to define clinical phenotypes of the disease based on the clinical outcome status (COS). The committee chose to examine patients five years after diagnosis to determine the COS. Several features of the disease were incorporated into the final nine categories of the disease. These included the current or past need for systemic therapy, the resolution of the disease, and current status of the condition. Sarcoidosis patients who were African American or older were likely to have a higher COS, indicating more chronic disease. The COS may be useful in future studies of sarcoidosis.
Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force / Baughman, Rp; Nagai, S; Balter, M; Costabel, U; Drent, M; du Bois, R; Grutters, Jc; Judson, Ma; Lambiri, I; Lower, Ee; Muller Quernheim, J; Prasse, A; Rizzato, G; Rottoli, P; Spagnolo, Paolo; Teirstein, A.. - In: SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES. - ISSN 1124-0490. - STAMPA. - 28(1):(2011), pp. 56-64.
Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force
SPAGNOLO, Paolo;
2011
Abstract
The clinical outcome of sarcoidosis is quite variable. Several scoring systems have been used to assess the level of disease and clinical outcome. The definition of clinical phenotypes has become an important goal as genetic studies have identified distinct genotypes associated with different clinical phenotypes. In addition, treatment strategies have been developed for patients with resolving versus non resolving disease. A task force was established by the World Association of Sarcoidosis and Other Granulomatous diseases (WASOG) to define clinical phenotypes of the disease based on the clinical outcome status (COS). The committee chose to examine patients five years after diagnosis to determine the COS. Several features of the disease were incorporated into the final nine categories of the disease. These included the current or past need for systemic therapy, the resolution of the disease, and current status of the condition. Sarcoidosis patients who were African American or older were likely to have a higher COS, indicating more chronic disease. The COS may be useful in future studies of sarcoidosis.File | Dimensione | Formato | |
---|---|---|---|
Sarcoidosis Vasc Diffuse Lung Dis_Baughman.doc
Accesso riservato
Tipologia:
Abstract
Dimensione
27 kB
Formato
Microsoft Word
|
27 kB | Microsoft Word | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris